Showing results (61-70 of 79) with videos related to

Sort By:
Pageof 8
International Journal of Cardiology|May 1, 2016
New therapy, new challenges: The effects of long-term continuous flow left ventricular assist device on inflammationLiza Grosman-Rimon, Filio Billia, Avi Fuks, et al.
Mabs|August 30, 2018
Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin AmericaMorton Scheinberg, Carlos Pineda, Gilberto Castañeda-Hernández, et al.
Advances in Therapy|May 24, 2020
The Promise for Histone Methyltransferase Inhibitors for Epigenetic Therapy in Clinical Oncology: A Narrative ReviewHope S Rugo, Ira Jacobs, Shikhar Sharma, et al.
Future Oncology (London, England)|May 28, 2021
Race and ethnicity representation in clinical trials: findings from a literature review of Phase I oncology trialsD Ross Camidge, Haeseong Park, Karen E Smoyer, et al.
The Journal of Thoracic and Cardiovascular Surgery|October 31, 2015
Increased cyclic guanosine monophosphate levels and continuous-flow left-ventricular assist devices: Implications for gastrointestinal bleedingLiza Grosman-Rimon, Laura C Tumiati, Avi Fuks, et al.
Nutrients|June 6, 2020
Energy Balance of Canadian Armed Forces Personnel during an Arctic-Like Field Training ExerciseMavra Ahmed, Iva Mandic, Elliot Desilets, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 20, 2012
Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of boneDaniel G Branstetter, Scott D Nelson, J Carlos Manivel, et al.
Clinical Rheumatology|October 14, 2016
Differentiating biosimilarity and comparability in biotherapeuticsValderilio Azevedo, Brian Hassett, João Eurico Fonseca, et al.
JAMA Oncology|May 31, 2019
Assessment of Subcutaneous vs Intravenous Administration of Anti-PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors: A Phase 1 Dose-Escalation TrialMelissa L Johnson, Fadi Braiteh, Juneko E Grilley-Olson, et al.
Oncology|April 6, 2021
The Use of Patient-Reported Outcome Measures in Phase I Oncology Clinical TrialsRobert L Coleman, J Thaddeus Beck, Joaquina C Baranda, et al.
Pageof 8